MD20070265A - Forme polimorfe de rifaximina, procedeu deobtinere a lor si utilizarea lor la fabricarea preparatelor medicamentoase - Google Patents

Forme polimorfe de rifaximina, procedeu deobtinere a lor si utilizarea lor la fabricarea preparatelor medicamentoase

Info

Publication number
MD20070265A
MD20070265A MDA20070265A MD20070265A MD20070265A MD 20070265 A MD20070265 A MD 20070265A MD A20070265 A MDA20070265 A MD A20070265A MD 20070265 A MD20070265 A MD 20070265A MD 20070265 A MD20070265 A MD 20070265A
Authority
MD
Moldova
Prior art keywords
production
rifaximin
medicinal preparations
epsilon
delta
Prior art date
Application number
MDA20070265A
Other languages
English (en)
Other versions
MD4081F2 (ro
MD4081G2 (ro
Inventor
Giuseppe C. Viscomi
Manuela Campana
Donatella Confortini
Maria Mariam Barbanti
Dario Braga
Original Assignee
Alfa Wassermann S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34934045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20070265(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann S.P.A. filed Critical Alfa Wassermann S.P.A.
Publication of MD20070265A publication Critical patent/MD20070265A/ro
Publication of MD4081F2 publication Critical patent/MD4081F2/ro
Publication of MD4081G2 publication Critical patent/MD4081G2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
    • C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
    • C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Inventia se refera la medicina, in special la farmacologie. Esenta inventiei consta in aceea ca se revendica formele polimorfe Delta si Epsilon de rifaximina, procedeul de obtinere si utilizarea lorpentru fabricarea diferitor forme de remedii medicamentoase cu actiune antibiotica pentru administrare orala si locala. Procedeul de obtinere a formelor Delta si Epsilon de rifaximina consta in cristalizarea produsului prin diluarea rifaximinei brute in alcool etilic si precipitarea prin adaugareaapei la o anumita temperatura si intr-o perioada stabilita de timp cu uscarea ulterioara in conditii de vid sau la o presiune atmosferica normala pana la atingerea unui continut anumit de apa in produsul finit.
MDA20070265A 2005-03-03 2006-02-27 Forme polimorfe de rifaximină, procedee de obţinere şi utilizare a acestora în calitate de preparate medicamentoase cu activitate antibiotică MD4081G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05004695.2A EP1698630B1 (en) 2005-03-03 2005-03-03 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
PCT/EP2006/001755 WO2006094662A1 (en) 2005-03-03 2006-02-27 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal

Publications (3)

Publication Number Publication Date
MD20070265A true MD20070265A (ro) 2008-05-31
MD4081F2 MD4081F2 (ro) 2010-12-31
MD4081G2 MD4081G2 (ro) 2011-07-31

Family

ID=34934045

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20070265A MD4081G2 (ro) 2005-03-03 2006-02-27 Forme polimorfe de rifaximină, procedee de obţinere şi utilizare a acestora în calitate de preparate medicamentoase cu activitate antibiotică

Country Status (28)

Country Link
US (9) US8193196B2 (ro)
EP (1) EP1698630B1 (ro)
JP (2) JP5737825B2 (ro)
KR (1) KR100885755B1 (ro)
CN (1) CN1900077B (ro)
AU (1) AU2006222312B8 (ro)
BR (1) BRPI0608073A8 (ro)
CA (1) CA2594789C (ro)
DK (1) DK1698630T3 (ro)
ES (1) ES2522895T3 (ro)
HK (1) HK1096396A1 (ro)
HR (1) HRP20070433B1 (ro)
IL (1) IL184694A0 (ro)
MA (1) MA29345B1 (ro)
MD (1) MD4081G2 (ro)
ME (1) ME00272B (ro)
MX (1) MX2007010742A (ro)
NO (1) NO342197B1 (ro)
NZ (1) NZ556737A (ro)
PL (1) PL1698630T3 (ro)
PT (1) PT1698630E (ro)
RS (1) RS54570B1 (ro)
RU (1) RU2397985C2 (ro)
SI (1) SI1698630T1 (ro)
TN (1) TNSN07292A1 (ro)
UA (1) UA89809C2 (ro)
WO (1) WO2006094662A1 (ro)
ZA (1) ZA200707397B (ro)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EA021176B1 (ru) 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
RU2519649C2 (ru) 2008-02-26 2014-06-20 Саликс Фармасьютикалз, Лтд. Способы лечения заболеваний кишечника
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
US8980872B2 (en) 2008-09-26 2015-03-17 Aska Pharmaceutical Co., Ltd. Agent for preventing and/or treating functional gastrointestinal disorder
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
JP2013504597A (ja) 2009-09-13 2013-02-07 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）の治療方法
CA2781580A1 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN101836959A (zh) * 2010-05-20 2010-09-22 山东达因海洋生物制药股份有限公司 一种制备几乎无苦味利福昔明干混悬剂的方法
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
MY165086A (en) 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CN103827122B (zh) 2011-02-11 2016-08-31 萨利克斯药品有限公司 利福昔明的形式及其用途
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2854380A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
AU2014229467A1 (en) 2013-03-15 2015-08-06 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US20150103715A1 (en) * 2013-10-14 2015-04-16 Qualcomm Incorporated Downlink control format indicator
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (en) 2014-04-19 2017-10-25 Granules India Limited An improved process for the preparation of rifamycin derivatives
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
EP3434265B1 (en) * 2016-03-24 2021-07-07 Sandoz AG Pharmaceutical composition containing rifaximin alpha & delta
EP3536311B1 (en) 2016-03-24 2021-12-22 Sandoz AG Storage stable composition comprising rifaximin alpha
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
WO2018197538A1 (en) 2017-04-26 2018-11-01 Sandoz Ag Oral dosage form comprising rifaximin in form beta
IT201700091912A1 (it) * 2017-08-08 2019-02-08 Biofer Spa Nuove pirido-imidazo rifamicine
DK3645539T3 (da) 2017-06-26 2021-05-10 Biofer Spa Pyrido-imidazo-rifamycin-derivater som antibakterielt middel
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
EP4034091A1 (en) 2019-09-24 2022-08-03 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043847A1 (ro) 1969-05-30 1971-02-19 Takeda Chemical Industries Ltd
CH571064A5 (en) 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
DE69111607T2 (de) * 1990-06-29 1995-12-21 Lepetit Spa Reine kristalline form von rifapentin.
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6271001B1 (en) 1995-03-23 2001-08-07 Bio Polymers Pty. Ltd. Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
DK0935417T3 (da) 1996-10-16 2009-08-10 Napo Pharmaceuticals Inc Enteroformuleringer af proanthocyanidin-polymer-sammensætninger mod diarré
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP4180368B2 (ja) * 2000-10-31 2008-11-12 サンド・アクチエンゲゼルシヤフト 塩酸ベンラファキシンの結晶形
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
EP1383512B1 (en) 2001-05-03 2004-09-08 Farmigea S.P.A. Use of sucralfate for the treatment of cervical erosion
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DK1512404T3 (da) 2002-06-03 2010-01-04 Cac Corp Eksterne præparater til behandling af dermatitis
CZ13908U1 (cs) 2003-10-08 2004-01-05 Cpn Spol. S R.O. Kosmetický přípravek s vysokomolekulární antioxidační složkou
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20070281960A1 (en) 2004-07-16 2007-12-06 Amar Lulla Anti-Histaminic Composition
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
NZ575550A (en) 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
DK2011486T3 (da) 2007-07-06 2012-09-03 Lupin Ltd Farmaceutiske sammensætninger af rifaximin
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
JP2010259452A (ja) * 2007-08-21 2010-11-18 Konica Minolta Medical & Graphic Inc 画像診断支援装置及び画像診断支援方法
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EA021176B1 (ru) 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
RU2519649C2 (ru) 2008-02-26 2014-06-20 Саликс Фармасьютикалз, Лтд. Способы лечения заболеваний кишечника
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
JP5276505B2 (ja) * 2009-04-06 2013-08-28 株式会社ユニバーサルエンターテインメント 遊技機
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
MX2011013427A (es) 2009-06-15 2012-04-20 Salix Pharmaceuticals Ltd Modulacion de exposicion sistemica a rifaximina.
JP2013504597A (ja) 2009-09-13 2013-02-07 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）の治療方法
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
PE20121185A1 (es) 2009-10-27 2012-09-15 Lupin Ltd Dispersion solida de rifaximina
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
KR20120099731A (ko) 2009-11-23 2012-09-11 시플라 리미티드 국소용 폼 조성물
CA2781580A1 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US9211258B2 (en) 2010-03-10 2015-12-15 Lupin Limited Rifaximin ready-to-use suspension
TR201810936T4 (tr) 2010-04-23 2018-08-27 Industrial Chemicals Group Ltd Deterjan bileşimi.
CN103269587A (zh) 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
EP2582707A4 (en) 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
MY165086A (en) 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
EP2616044A1 (en) 2010-09-13 2013-07-24 Cilpa Limited Pharmaceutical composition
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
CN103827122B (zh) 2011-02-11 2016-08-31 萨利克斯药品有限公司 利福昔明的形式及其用途
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2854380A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
CA2861104A1 (en) 2012-01-25 2013-08-01 Salix Pharmaceuticals, Ltd. Rifaximin derivative and uses thereof
JP2013184902A (ja) 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
MX2015015700A (es) 2013-05-17 2016-06-02 Salix Pharmaceuticals Inc Metodos para usar rifaximina en exploraciones de tomografia por emision de positrones (pet).
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (en) 2014-04-19 2017-10-25 Granules India Limited An improved process for the preparation of rifamycin derivatives
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
WO2016063289A2 (en) 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
WO2017021975A1 (en) 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3434265B1 (en) 2016-03-24 2021-07-07 Sandoz AG Pharmaceutical composition containing rifaximin alpha & delta
EP3536311B1 (en) 2016-03-24 2021-12-22 Sandoz AG Storage stable composition comprising rifaximin alpha
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018158646A1 (en) 2017-03-02 2018-09-07 Granules India Limited Rifaximin crystalline form
WO2018178777A1 (en) 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
WO2018197538A1 (en) 2017-04-26 2018-11-01 Sandoz Ag Oral dosage form comprising rifaximin in form beta
DK3645539T3 (da) 2017-06-26 2021-05-10 Biofer Spa Pyrido-imidazo-rifamycin-derivater som antibakterielt middel

Also Published As

Publication number Publication date
CA2594789C (en) 2010-09-14
CN1900077B (zh) 2012-04-11
UA89809C2 (uk) 2010-03-10
PT1698630E (pt) 2014-09-15
RU2397985C2 (ru) 2010-08-27
TNSN07292A1 (en) 2008-12-31
CN1900077A (zh) 2007-01-24
CA2594789A1 (en) 2006-09-14
US8741904B2 (en) 2014-06-03
NZ556737A (en) 2011-11-25
WO2006094662A1 (en) 2006-09-14
ZA200707397B (en) 2009-03-25
MX2007010742A (es) 2007-09-12
NO342197B1 (no) 2018-04-16
AU2006222312B2 (en) 2011-11-03
US10703763B2 (en) 2020-07-07
AU2006222312A1 (en) 2006-09-14
US8193196B2 (en) 2012-06-05
RS54570B1 (en) 2016-06-30
JP5737825B2 (ja) 2015-06-17
US20180291032A1 (en) 2018-10-11
US9271968B2 (en) 2016-03-01
US20200002350A1 (en) 2020-01-02
MD4081F2 (ro) 2010-12-31
US20150073007A1 (en) 2015-03-12
EP1698630A8 (en) 2006-10-25
JP2013216710A (ja) 2013-10-24
ES2522895T3 (es) 2014-11-19
EP1698630B1 (en) 2014-09-03
JP2008531623A (ja) 2008-08-14
US20090130201A1 (en) 2009-05-21
US20200277301A1 (en) 2020-09-03
US8518949B2 (en) 2013-08-27
BRPI0608073A2 (pt) 2009-11-03
US20120245355A1 (en) 2012-09-27
MD4081G2 (ro) 2011-07-31
SI1698630T1 (sl) 2015-01-30
US20160362419A1 (en) 2016-12-15
MEP34408A (en) 2011-02-10
KR20060096242A (ko) 2006-09-11
HRP20070433A2 (en) 2007-11-30
IL184694A0 (en) 2007-12-03
PL1698630T3 (pl) 2014-12-31
ME00272B (me) 2011-05-10
BRPI0608073A8 (pt) 2017-12-26
EP1698630A1 (en) 2006-09-06
US20220119403A1 (en) 2022-04-21
DK1698630T3 (da) 2014-12-08
NO20074988L (no) 2007-11-30
HRP20070433B1 (hr) 2015-02-27
KR100885755B1 (ko) 2009-02-26
RS20070364A (en) 2009-01-22
AU2006222312B8 (en) 2011-11-17
US20130310410A1 (en) 2013-11-21
MA29345B1 (fr) 2008-03-03
HK1096396A1 (en) 2007-06-01
RU2007136430A (ru) 2009-04-10

Similar Documents

Publication Publication Date Title
MD20070265A (ro) Forme polimorfe de rifaximina, procedeu deobtinere a lor si utilizarea lor la fabricarea preparatelor medicamentoase
JO2470B1 (en) Polycrystalline image of rifaximin, processes for its production and use in medicinal preparations.
EP2436700B8 (en) Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2008012343A3 (en) Macrolide synthesis process
WO2008155069A3 (de) Substituierte oxazolidinone und ihre verwendung
TN2009000030A1 (en) Use of polyols to obtain stable polymorphous forms of rifaximin
WO2008006979A3 (fr) Procede de preparation de composes diaminophenothiazinium.
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
IL195142A (en) Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases
UA98303C2 (ru) Способ синтеза макролидов
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2012036907A3 (en) Broad spectrum antibiotic arylomycin analogs
MY175804A (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
IL185529A0 (en) A method of producing a glazed cereal product with isomalt and cereal products produced thereby
MY145448A (en) Acylated nonadepsipeptides used as lysobactin derivatives
WO2007095661A8 (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
IL187001A0 (en) Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
WO2008041176A3 (en) Process for the preparation of form i and form ii of ritonavir
ITRM20050074A1 (it) Miscela da utilizzare per la produzione di trasferibili per decalcomania, prodotto trasferibile per decalcomania e relativo procedimento di produzione, e procedimento di decalcomania utilizzante tale prodotto trasferibile.
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
WO2006135656A3 (en) Processes for the preparation of paclitaxel
GB2441902A (en) Novel method for preparing ginseng to obtain increased amount of ginsenoside RG5
GB0716348D0 (en) Molecular separation process in various steps of process for production of chlorinated sugars, their precursors and derivatives

Legal Events

Date Code Title Description
FG4A Patent for invention issued
TC4A Change of name of proprietor (patent for invention)

Owner name: ALFASIGMA S.P.A., IT VIALE SARCA N. 223, MILANO (M

Free format text: PREVIOUS NAME OF PROPRIETOR: ALFA WASSERMANN S.P.A., IT VIA ENRICO FERMI, 1, I-65020 ALANNO (PE), ITALIA